Clinical Trials Logo

Eye Diseases clinical trials

View clinical trials related to Eye Diseases.

Filter by:

NCT ID: NCT05768152 Not yet recruiting - Eye Diseases Clinical Trials

Repeated Low-Level Red-Light Therapy Shortens Axial Length

Start date: March 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to investigate the incidence and magnitude of axial length shortening after repeated low-level red-light therapy in high myopia children and teenagers.

NCT ID: NCT05759208 Completed - Dry Eye Disease Clinical Trials

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

Start date: April 28, 2023
Phase: Phase 2
Study type: Interventional

The objective of this study is to compare the safety and efficacy of OK-101 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

NCT ID: NCT05758753 Enrolling by invitation - Dry Eye Disease Clinical Trials

QST for Corneal Nerve Function

Start date: May 16, 2023
Phase: N/A
Study type: Interventional

This study is designed to learn more about the impact different types of stimuli, such as heat, cold and vibration, can have on ocular pain response. This is called quantitative sensory testing (QST). Most procedures being performed in this study, except the QST, are standard of care which means they are performed during the participant's routine eye examination.

NCT ID: NCT05753189 Completed - Presbyopia Clinical Trials

Phase 3 Safety Study for the Treatment of Presbyopia Subjects

Start date: February 21, 2023
Phase: Phase 3
Study type: Interventional

Safety Study of the Long-Term Safety of LNZ101 in Presbyopic Subjects

NCT ID: NCT05745064 Completed - Dry Eye Disease Clinical Trials

A Study of TL-925 as a Treatment for Dry Eye Disease

Start date: February 27, 2023
Phase: Phase 2
Study type: Interventional

In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: 2-weeks screening/run-in and 4-weeks double-masked treatment.

NCT ID: NCT05743764 Completed - Dry Eye Disease Clinical Trials

HU007 in Patients With Dry Eye Syndrome

Start date: March 23, 2023
Phase: Phase 3
Study type: Interventional

A multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye Drops Controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome

NCT ID: NCT05741398 Recruiting - Dry Eye Syndromes Clinical Trials

Evaluation of Optical System in the Treatment of - Dry Eye Disease

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Single-center, Prospective, Open Label, with Before-After Study Design, to evaluate the safety and efficacy of the optical system in the treatment of dry eye disease.

NCT ID: NCT05738629 Not yet recruiting - Dry Eye Disease Clinical Trials

Safety and Efficacy of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops Treatment for Dry Eye Diseases Post Refractive Surgery and Associated With Blepharospasm

Start date: March 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the preliminary safety and effectiveness of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops in the treatment of dry eye diseases post refractive surgery and associated with blepharospasm

NCT ID: NCT05731154 Completed - Thyroid Eye Disease Clinical Trials

Development of an AI Solution to Evaluate Clinical Activity of TAO Using Periocular Images Taken by Smartphones in Patients With Thyroid Dysfunction

Start date: December 22, 2021
Phase:
Study type: Observational

This study was conducted to develop an AI solution to evaluate clinical activity score (CAS) of thyroid associated orbitopathy (TAO) using periocular selfie images taken by smartphones in patients with thyroid dysfunction. An AI solution to evaluate CAS in TAO was developed in previous retrospective study using periorbital digital images taken by DSLR camera in the studio. This AI solution will be adjusted to show its best performance with periocular selfie images taken by smartphones.

NCT ID: NCT05728944 Completed - Presbyopia Clinical Trials

Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia

CLARITY
Start date: April 24, 2023
Phase: Phase 3
Study type: Interventional

Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia